Jane Lenehan, Scientific Animal Protection Manager (acting)

Slides:



Advertisements
Similar presentations
From POM to P From POM to P Wellard’s NHS training wellards.co.uk 2004.
Advertisements

Merton V. Smith, Ph.D., J.D. Director International Programs Center for Veterinary Medicine U.S. Food and Drug Administration Governance of Veterinary.
IMP/Placebo Sourcing, Release, Storage and Reconciliation. Ms Caroline Whiriskey Research Pharmacist, HRB Clinical Research Facility Galway.
THE MEDICINES CONTROL COUNCIL (MCC) Presentation to the Portfolio Committee on Health 24 June 2008.
Clinical Trials — A Closer Look. The Food and Drug Administration (FDA) is the main consumer watchdog for numerous products: Drugs and biologics (prescription.
Project IMPACT IMPACT National Medical Association What African Americans Should Know About Clinical Trials You’ve Got the Power!
Licensing of Nuclear Power Plants in Pakistan
INFLUENCE OF CONSUMER PERCEPTION ON NEW FOOD PRODUCT DEVELOPMENT.
EMEA / IFAH–Europe Info Day « Balancing the benefits and risks of Veterinary Medicinal Products »
REGISTRATION OF MEDICINES & PROGRESS WITH RESTRUCTURING THE MCC 1.
Great Plains Veterinary Educational Center A Little On Drug Use Antibiotic Use GuidelinesAMDUCA (Animal Medicinal Drug Use Clarification Act)ELDU (Extra.
DOMESTICATION OF TRIPS FLEXIBILITIES IN NATIONAL IP LEGISLATION FOR STRENGTHENING ACCESS TO MEDICINES IN ZAMBIA AN OVERVIEW OF PATENT PROTECTION IN ZAMBIA.
Good Clinical Practice (GCP)- An introduction Dr Noor Ibrahim Mohamed Sakian.
Jasper Ogwal-Okeng Gulu University Research Workshop 3 rd -6 th March 08.
Activity #3 Testing Medicines: A Clinical Trial. Key Words Clinical Trial – a test performed on volunteers, typically to test medicines, before the products.
A S Nanivadekar Introduction to GCP. A S Nanivadekar Outline Definition and scope Definition and scope Purpose of clinical research Purpose of clinical.
VETERINARY PHARMACY Elizabeth Shipley.
EU Council Directive on Traditional Herbal Medicinal Products Dr. Dairine Dempsey IRISH MEDICINES BOARD for IHTA AGM 23 rd April 2003.
Cardiff and Vale UHB Bwrdd lechyd Prifysgol Caerdydd a’r Fro NHS R&D Overview How to avoid the common pitfalls? Thomas Fairman Research Liaison Manager.
1 10 th Annual European Scientific and Regulatory Affairs Conference New Pharmaceutical legislation: One year experience… 21 November 2006 Bernard Lemoine.
Science, research and development European Commission IDARI Project Meeting Tartu, June 2005 Martin Greimel Scientific Officer Directorate-E ‘Biotechnology,
1/33.  What is INDA ?  Types of INDAs  Objectives of INDAs  Format & Contents of an INDA  IND Safety reports  IND Annual Reports  IND Review Process.
The New Drug Development Process (www. fda. gov/cder/handbook/develop
Ivowen Ltd1 Ivowen Limited Preparation and Submission of a Traditional Herbal Medicinal Product Application.
History of Pediatric Labeling
LOCAL AUTHORITY REGULATORY ASPECTS Paul Carroll Executive Scientific Officer Waterford County Council Integrated Constructed Wetlands Awareness Seminar.
European Patients’ Academy on Therapeutic Innovation Aspects of pharmacovigilance: Post-Authorisation Safety Studies (PASS)
PharmacoVigilance: Development of PhV systems and processes.
1 CHALLENGES IN REGULATION OF TRADITIONAL AND ALTERNATIVE MEDICINES 24 th March, 2010 MOHSW Conference Room Registration of Herbal Drugs.
PharmacoVigilance: Development of PhV systems and processes VICH Workshop, Dar Es Salaam, Tanzania, 24 June 2015.
An agency of the European Union Principles for the assessment and authorisation of antimicrobials in the EU VICH Outreach Forum, October 2015 Presented.
Link between legal framework of VMP regulation and VICH GLs in Japan Takashi Kozasa DVM Ministry of Agriculture, Forestry and Fisheries Government of Japan.
1 IND Applications for Academic Clinical Investigations John Marler, MD US Food and Drug Administration New Hampshire Avenue White Oak, MD
GCP (GOOD CLINICAL PRACTISE)
Clinical Trials.
ICORD 2006 Kerstin Westermark Md, PhD, Assoc. prof. COMP Chairperson.
Drug Development Process Stages involved in Regulating Drugs
CLINICAL TRIALS.
Off-label Use.
POST APPROVAL CHANGE MANAGEMENT PROTOCOLS IN THE EUROPEAN UNION
A capacity building programme for patient representatives
Recent Evolution of New Drug Review and Approval System in Korea
PAEDIATRIC REGULATION
Requirements for GLP and GCP in the EU
Regulation EU 536/2014 on clinical trials
You’ve Got the Power! What African Americans Should Know About Clinical Trials National Medical Association.
EudraVigilance.
Clinical Trials — A Closer Look
REGULATORY PROBLEMS IN CARING OUT PRE- AND POST- AUTHORISATION CLINICAL TRIALS Dr Penka Decheva GCP Inspector, BDA.
Pharmacovigilance in clinical trials
UK Legal Requirement for Notification of Serious Breaches of Good Clinical Practice or The Trial Protocol John Poland, PhD Senior Director, Regulatory.
Multinational collaboration in the Authorisation of VMPs: the EU approach VICH Outreach Forum Tokyo, Nov 2017 Noel Joseph European Commission.
TAIEX, Istanbul, April 19th, 2011
The role of the HPRA in the authorisation of veterinary medicinal products The role of the Health Products Regulatory Authority in the authorisation of.
577 marketing authorisations granted (356 active ingredients) by EU centralized procedure, marketing authorisations granted (339 active ingredients)
Amanda Lilley-Kelly Senior Trial Co-ordinator
The Intern
Anne Hayes, Inspection Manager
Pharmacovigilance updates
Changing the Reference Member State (RMS)
HPRA delivery on strategic plan
Developments in the EU medicines regulatory network
Useful points of contact for stakeholders
SPIRIT diagram. SPIRIT diagram. The figure details the timing of enrollment activities, intervention allocation, and assessments of outcomes over the course.
Pharmaceutical Industry Feedback HPRA Performance
Veterinary antibiotic consumption in Ireland
P O S S I B L E F U T U R E N A T I O N A L L E G I S L A T I O N
Pharmacovigilance inspections: what HPRA expects
Use an Appropriate Veterinarian/Client/Patient Relationship (VCPR) as the Basis for Medication Decision-Making Good Production Practice #1 Assuring Quality.
Presentation transcript:

Jane Lenehan, Scientific Animal Protection Manager (acting) Clinical Trials and Testing of Veterinary Medicinal Products in Ireland Jane Lenehan, Scientific Animal Protection Manager (acting) HPRA Veterinary Medicines Information Day 13 June 2018, Hilton Hotel Dublin Airport

Today’s talk Background Application process HPRA evaluation Fees Conclusion 18/04/2019

1. Background

Legislation: Directive 2001/82/EU and SI No 786 of 2007 as amended Scope Legislation: Directive 2001/82/EU and SI No 786 of 2007 as amended Clinical trial: a study which aims to examine under normal field conditions the safety/efficacy of a veterinary medicinal product (VMP) for the purpose of obtaining a marketing authorisation or a change thereof. 18/04/2019

Purpose of a clinical trial To demonstrate/substantiate effect of a VMP after administration at recommended dosage To specify: indications & contraindications according to species/age/breed/sex directions for use adverse reactions safety and tolerance under normal conditions of use 18/04/2019

HPRA 2016 survey on clinical trials in Ireland Feedback: Expertise in Ireland Proximity to R&D facilities Cost & speed of applications Confusion about legislation 18/04/2019

2. Application process

Clinical trial application HPRA licence required prior to commencing any trial in Ireland HPRA must consult with the Department of Agriculture, Food and the Marine (DAFM) before granting a licence A copy of application should be sent to DAFM (at time of HPRA application) 18/04/2019

Includes permission to import test product Timeline R&V Evaluation Queries Complete evaluation Licensing Committee Licence issued 40 working days Includes permission to import test product DAFM input 18/04/2019

3. Clinical trial evaluation

For veterinary field trial use only Key requirements Detailed trial protocol Trials under veterinary care Informed owner consent Good Clinical Practice (GCP) conditions Control animals Positive control Placebo Untreated control For veterinary field trial use only 18/04/2019

Key areas of evaluation Trial locations Quantities of test/control medicines to be imported (where no marketing authorisation in place) Withdrawal periods in food- producing species 18/04/2019

4. Fees

Current Application Fees €630 New trial – medicine containing a novel substance €315 New trial – medicine containing established ingredient €60 Variation to a current licence 18/04/2019

5. Conclusion

Main evaluation by HPRA with input from DAFM 40 working day timeline Summary Main evaluation by HPRA with input from DAFM 40 working day timeline Fees €315/ €630 Requirements include GCP, control animals, owner consent, veterinary care, etc. 18/04/2019

vetinfo@hpra.ie www.hpra.ie/homepage/veterinary/regulatory-information For more information www.hpra.ie/homepage/veterinary/regulatory-information vetinfo@hpra.ie 18/04/2019